The case for & against
Bull & Bear analysis
Bearish
Cybin Inc. (NASDAQ: CYBN) is an emerging biotechnology company operating in the psychedelic therapeutics space, focusing on developing novel compounds aimed at treating mental health disorders such as depression and anxiety. The company has made significant advancements in its drug development pipeline with compounds leveraging psychedelic properties, positioning itself favorably within the growing mental health treatment landscape amidst rising awareness and acceptance of psychedelic-based therapies.
Bull says
- ↑52-week high of $13.24 and $48.60 average price target from five analysts indicating strong buy sentiment.
- ↑Completed Phase 2 CYB004 enrollment and advancing Phase 3 CYB003 with readouts expected by year-end.
- ↑Cash position of $75.2M and 74 preclinical studies completed support R&D runway.
- ↑700M people affected by mental health disorders underscore large market opportunity.
- ↑Schedule I manufacturing license and 50+ partnerships enable cost-efficient drug development.
- ↑Potential >90% upside by Sept 2026 with improving operating leverage and strong momentum factors.
Bear says
- ↓Q2 net loss of $17.6M and $12M operating expenses signal steep cash burn.
- ↓AltIndex forecast projects 5% downside to $7.86, suggesting valuation headwinds.
- ↓Phase 2/3 efficacy and patient adherence risks could delay or derail trials.
- ↓Complex psychedelic regulatory landscape may introduce delays or additional IND requirements.
- ↓Potential weak earnings yield and high short interest reflect negative market sentiment.
- ↓Competition from CMPS, ATAI, MNMD intensifies disruption risk and pressures future growth.
Earnings Call · Q2 2022 · Mgmt. Guidance
Updated 09-05-2026bullish
Transcript signals
Bull points
- Good afternoon ladies and gentlemen and thank you for standing by welcome to CYBIN's second quarter fiscal year 2022 earnings call.
- To achieve this, we have assembled a team comprised of world-class scientists, industry leaders, and external partners so that together we can push the boundaries.
- We are working hard to create an infrastructure to support the scientific exploration and push the boundaries.
Bear points
- Our net loss was $17.6 million for the quarter ended September 30th, 2021, of which non-cash expenses totaled $6 million and cash-based operating expenses totaled $11.6 million.
Read full transcript analysis ›